Imatinib resistance: diagnostic and therapeutic choices

Abstract

We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted in toxicity. She obtained a complete molecular response to therapy with nilotinib, without adverse events.

Keywords

• Imatinib resistance
• Blood level test
• Nilotinib